# Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed

> **NCT00004254** · PHASE2 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 25 (actual)

## Conditions studied

- Malignant Mesothelioma

## Interventions

- **DRUG:** raltitrexed

## Key facts

- **NCT ID:** NCT00004254
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-11
- **Primary completion:** 2001-06
- **Final completion:** —
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2012-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004254, "Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00004254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*